WO2018199631A1

WO2018199631A1 - Method for quantifying hydrophobic component in liquid using contact area diffusion factor and method for providing information on diagnosis of disease using same

Info

Publication number: WO2018199631A1
Application number: PCT/KR2018/004808
Authority: WO
Inventors: 이상현
Original assignee: 주식회사 펨토바이오메드
Priority date: 2017-04-26
Filing date: 2018-04-25
Publication date: 2018-11-01
Also published as: JP2019521338A; KR20180120109A; JP6799086B2; KR102086840B1

Abstract

A method for quantifying a hydrophobic component contained in a liquid according to the present invention comprises the steps of: a) bringing a droplet of a liquid into contact with a solid surface and measuring an initial area (A0) and an initial diameter (d0) of a contact area between the droplet and the solid surface; b) measuring an area (At) and a diameter (dt) of a contact area between the droplet and the solid surface after a predetermined time (t) has elapsed; and c) obtaining a contact area diffusion factor (CADF).

Description

Method of quantifying hydrophobic components in liquid using contact surface diffusion coefficient and providing information on diagnosis of disease using the same

The present invention relates to a method for quantifying hydrophobic components, specifically fat components, contained in a liquid using a contact area diffusion coefficient (CADF) on a solid surface of a liquid and metabolic diseases or dementia, specifically diabetes. The present invention relates to a method for predicting the onset of fat embolism or dementia or for providing information for diagnosing the onset or course of the diseases.

Social costs for dementia have been higher than the total costs for cancer, heart disease and stroke, and dementia-related health care costs are expected to double every 10 years. According to a report published in the New England Journal of Medicine by the US Land Corporation, a nonprofit private research organization, the family and social costs of Alzheimer's and other dementia patients are estimated at approximately $ 157 billion, and the annual treatment costs of dementia patients are 56,000 per person. It is expected to be dollars. Alzheimer's disease, the most common symptom of dementia, currently numbered 5.3 million in the United States and is the sixth leading cause of death.

However, despite the high cost of treating dementia, it is impossible to cure dementia at the current level of medical technology, and it is difficult to slow the progression of the disease because it is only a temporary relief of symptoms. This is because there is a lack of understanding of the definite pathological causes of dementia, and it is not possible to provide personalized treatment according to individual patient differences. Personalized care starts with the diagnosis of dementia patients in a convenient and low-cost way of daily life, and if personalized care becomes possible, it can be a great help to prevent the increase and cost of dementia patients.

Lipoembolism is one of the leading causes of death in the surgical procedure. Liposuction and orthopedic surgery, especially with a large number of surgeries per year, has a low mortality rate, but a high number of deaths each year. Is occurring.

Official statistics compiled in the 2009 International Society for Aesthetic Plastic Surgery (ISAPS) report show that liposuction is the largest plastic surgery of 21 plastic surgeries worldwide, with more than 1.6 million cases performed in Korea over the same period. It became.

Liposuction is the most frequently performed surgery in plastic surgery, but the risks that occur during liposuction are not well known to the public. Fat embolism is caused by the inflow of fat into the bloodstream through damaged blood vessels during liposuction, which can seriously impair lung function and penetrate other organs. Despite the relatively low incidence of fat embolism, hundreds of deaths are known worldwide due to very high mortality rates.

In order to prevent fat embolism that may occur during liposuction, the amount of fat introduced into the bloodstream before, during and after surgery should be measured from time to time, but there is no device for quantifying the amount of fat.

The present inventors have mentioned the contact surface diffusion coefficient (CADF) of the liquid and the method of measuring the amount of fat penetrated through the liquid in the preceding patent application (Korean Patent Application No. 10-2012-0147029). The CADF measuring method described in the above-mentioned prior application is to measure the degree of change in the contact diameter or the contact area of the droplet contacting surface in contact with the solid plane over time or by measuring the change in the amount of fatty components present in the liquid. Obtaining CADF.

However, in the CADF measurement method, since only one of the contact diameter and the contact area was selected and used as the measurement variable, the following realistic problems exist in accurately detecting the contact surface diffusion coefficient of the liquid.

In particular, when the initial contact surface between the droplet and the solid does not form a circular shape or when the change in the outer shape of the contact surface appears irregularly after a certain time, a measurement error increases when measuring the contact diameter or contact area of the contact surface after a certain time. There was a problem.

In addition, in the case of measuring CADF using only the contact area, in order to measure the contact area of the droplet in order to measure the contact area of the droplet, the contact boundary between the droplet and the solid cannot be accurately identified. There was a problem. Specifically, in the case of hydrophobic surfaces having a contact angle between the droplet and the solid surface larger than 90 °, since the diameter of the droplet is larger than that of the contact surface regardless of the upward or downward direction, the outer boundary of the droplet covers the contact boundary. It was difficult to discern the boundary of a contact surface correctly.

Even if the contact angle between the droplet and the solid surface is smaller than 90 °, the boundary between the droplet and the solid surface is continuously thinned, which makes it difficult to accurately identify the boundary when viewed from the top or the bottom in the vertical direction. there was.

In addition, when CADF is measured using only the contact diameter of the contact surface between the droplet and the solid surface, the shape of the droplet is observed from the lateral direction to identify both ends of the contact surface and the distance between the two ends is measured by the contact diameter. In many cases, the contact surface diffusion coefficient could not be accurately measured only by the change of contact diameter, which caused errors.

For these reasons, in order to achieve the accuracy of the measurements required to enable practical industrial use, the contact area diffusion coefficient has been improved by including both the contact area and contact diameter between the droplet and the solid surface as variables. Calculation method of was required.

Accordingly, the present inventors have completed a novel method for estimating a contact surface diffusion coefficient with improved accuracy while including a method for estimating a contact surface diffusion coefficient based on a contact area between a droplet and a solid surface and a method for calculating a contact surface diffusion coefficient based on a contact diameter. It came to the following.

The present invention relates to a method for quantifying hydrophobic components, specifically fat components, contained in a liquid by using a contact surface diffusion coefficient (CADF) on the solid surface of the liquid, and the possibility of developing a disease, in particular dementia, diabetes or fat embolism, using the same. An object of the present invention is to provide a method for predicting or providing information for diagnosing the onset or course of the diseases.

According to an embodiment of the present invention, a method for quantifying hydrophobic components contained in a liquid includes a) contacting a droplet of liquid to a solid surface, an initial area A ₀ of the contact surface between the droplet and the solid surface, and an initial of the contact surface. Measuring the diameter d ₀ ; b) after a predetermined time _t , measuring the area A _t of the contact surface between the droplet and the solid surface and the diameter d _t of the contact surface; And c) obtaining a contact surface diffusion coefficient (CADF) according to the following formula (1):

[Equation 1]

(Wherein n, m, N and M are constants)

According to one embodiment of the invention, the method of quantifying the hydrophobic component contained in the liquid further comprises the step of d) obtaining the content of the hydrophobic component contained in the droplet by using the contact surface diffusion coefficient and the following equation 2 can do:

[Equation 2]

(Wherein k, C ₀ , A, B, D, P and Q are correction constants)

According to one embodiment of the invention, the liquid may be a body fluid.

According to one embodiment of the invention, the body fluid may be selected from the group consisting of blood, serum, plasma, sweat and urine.

According to one embodiment of the invention, the hydrophobic component may be fat.

According to an embodiment of the present invention, a method of predicting the possibility of developing a metabolic disease or dementia or providing information on the onset or course of a metabolic disease or dementia includes a) contacting a droplet of a body fluid of a subject to be contacted with a solid surface, Measuring an initial area A ₀ of the contact surface between the solid surfaces and an initial diameter d ₀ of the contact surface; b) after a predetermined time _t , measuring the area A _t of the contact surface between the droplet and the solid surface and the diameter d _t of the contact surface; c) obtaining a contact surface diffusion coefficient (CADF) according to Equation 1 below; d) using the contact surface diffusion coefficient and the following formula 2 to obtain the content of the fat component contained in the droplets; And e) comparing the content of fat component obtained with the content of fat component obtained from the body fluids of a normal person:

[Equation 1]

(Wherein n, m, N and M are constants)

[Equation 2]

(Wherein k, C ₀ , A, B, D, P and Q are correction constants)

According to an embodiment of the present invention, if the difference in the amount of fat component obtained from the body fluid of the normal person from the content of fat component obtained from the body fluid of the judgment object is positive, there is a high possibility of developing metabolic disease or dementia or metabolic disease Or diagnose the development of dementia.

According to one embodiment of the invention, the disease may be selected from the group consisting of dementia, diabetes and fat embolism.

According to one embodiment of the invention, the dementia may be selected from the group consisting of Alzheimer's disease, Parkinson's disease vascular dementia, mixed dementia and mild cognitive impairment.

By using the method for quantifying the hydrophobic component contained in the liquid according to the present invention, the content of the fat component contained in the body fluid can be more accurately and simply by using a body fluid such as urine which can be obtained cheaply and conveniently from the test object. It can be measured.

In particular, the quantitative method according to the present invention increases the measurement accuracy of CADF by using both the contact area and the contact diameter of the droplet and the solid surface at the same time, and generates measurement errors caused by using only one of the contact area or the contact diameter. The likelihood can be greatly reduced.

1 shows three surface tensions acting along the contact boundary between the droplet and the solid surface.

FIG. 2 shows a graph comparing the CADF values of urine before (without fatty components) and after (without fatty components) liposuction.

Figure 3 shows the CADF value of the urine sample calculated every 0.5 days after liposuction.

Figure 4 shows a graph showing the relationship between the concentration of fat components and CADF obtained by varying the fat content concentration by diluting the urine sample containing fat components with ultrapure water after liposuction.

FIG. 5 shows a graph comparing fatty acid concentration conversion formulas by correcting the concentration of total fatty acids and CADF measurements measured by gas chromatography (GC).

Figure 6 shows a graph comparing the LDL value and CADF value of the fat component in the blood sample.

Figure 7 shows a graph comparing the fat component content in the urine of normal people and patients with six diseases measured by the GC method and the CADF method according to an embodiment of the present invention. At this time, the six diseases are diabetes (DM), Alzheimer's disease (AD), Parkinson's disease (PDD), vascular dementia (VD), mixed dementia (VD + AD), mild cognitive impairment (MCI).

8 shows an apparatus for measuring the concentration of hydrophobic components contained in a liquid according to an embodiment of the present invention.

EMBODIMENT OF THE INVENTION Hereinafter, embodiment which concerns on this invention is described in detail with reference to an accompanying drawing. The following description is only for easily understanding the embodiments of the present invention, but is not intended to limit the protection scope.

Method for quantifying the hydrophobic component contained in the liquid according to an embodiment of the present invention calculates the diffusion coefficient (CADF) of the contact surface when the droplet of the liquid contacts the solid surface, based on the hydrophobic component, For example, a method of quantifying fat component is provided.

The measuring principle is as follows.

As shown in FIG. 1, γ _gl is the surface tension between the gas and the liquid, γ _ls is the surface tension between the liquid and the solid surface, and γ _gs means the surface tension between the gas and the solid surface. Α is the contact angle of the droplet to the solid surface, and d is the contact diameter between the droplet and the solid surface.

When the droplets contact the solid surface, the three surface tensions are in balance with each other. Over time, evaporation of volatile components such as moisture from the droplets can occur, so that the volume of the droplets decreases and the area of contact with the solid surface also decreases. Therefore, the contact area of the droplets in contact with the solid surface is constant or decreased with time, and the contact area is rarely increased.

However, if the balance between the three surface tensions described above is broken, expansion of the contact area may occur. As such an example, an aqueous droplet containing a fatty component in a liquid may be mentioned. Fatty components are generally not mixed with water, but in small amounts can be mixed uniformly in water. Some fats can be dissolved in small amounts in water and stably mixed in water in the form of colloids. When fat is dissolved in an aqueous fluid, contacting the fluid in the form of droplets with the solid surface can cause the oil component to stick to the surface of the solid, thus breaking the balance of the three surface tensions described above.

The surface tension of water is generally stronger than the surface tension of hydrophobic or lipophilic materials. For this reason, if the hydrophobic component dissolved in the aqueous fluid sticks to the solid surface, the balance of the three surface tensions may be broken, leading to an increase in the contact area of the droplet. The amount of hydrophobic component, such as fat, that adheres to the solid surface is proportional to the fat concentration and surface adsorptivity in the aqueous fluid.

When an aqueous droplet containing a hydrophobic component is in contact with the hydrophobic surface, initially the fatty component hardly adheres to the solid surface, but over time, hydrophobic substances such as fat will stick to the hydrophobic solid surface, resulting in droplets and solids. The surface tension between the surfaces is varied, resulting in the contact area diffusion (CAD) phenomenon between the droplets and the solid surface.

A method for quantifying hydrophobic components contained in a liquid according to an embodiment of the present invention includes calculating the following CADF:

a) contacting a droplet of liquid to a solid surface and measuring an initial area A ₀ of the contact surface between the droplet and the solid surface and an initial diameter d ₀ of the contact surface;

b) after a predetermined time _t , measuring the area A _t of the contact surface between the droplet and the solid surface and the diameter d _t of the contact surface; And

c) obtaining a contact surface diffusion coefficient (CADF) according to the following formula:

[Equation 1]

Wherein n, m, N and M are constants.

Equation 1 is a calculation formula of the dimensionless CADF. Here, A _t is the contact area of the droplet after a predetermined time t has elapsed, and A ₀ is the initial contact area. d _t is the contact diameter of the droplet after a predetermined time t has elapsed, and d ₀ means the initial contact diameter.

In Equation 1, the constants n and m are respectively determined according to the sensitivity of the contact area and the contact surface diameter of the contact surface diffusion coefficient, and the constants N and M are the contact surface diffusion of the change ratio of the contact area and the change ratio of the contact diameter, respectively. Determined based on specific gravity for coefficients. Each constant can vary depending on the measurement environment of the contact surface diffusion coefficient.

Since the contact surface diffusion coefficient increases as the content (concentration) of the hydrophobic component such as the fatty component contained in the droplet increases, it is possible to quantify the content of the fatty component using the contact surface diffusion coefficient according to an embodiment of the present invention. The method for quantifying the hydrophobic component contained in the liquid using the obtained contact surface diffusion coefficient may further perform the following content calculation step:

d) obtaining the content of the hydrophobic component contained in the droplet by using the contact surface diffusion coefficient and the following equation:

[Equation 2]

Where k, C ₀ , A, B, D, P and Q are correction constants. The correction constants are determined to minimize errors through comparative corrections based on the measured data of CADF and fat content, respectively.

As used herein, the term "liquid" refers to a material having a volume to be measured but having an unfixed shape. The liquid may be a bodily fluid present in the body of an animal, including a human. As used herein, "body fluid" means, but is not limited to, blood, serum, plasma, sweat, urine, and the like of human or animal.

As used herein, the term "hydrophobic component" or "lipophilic component" means a component having a small affinity for water and having no polarity. The hydrophobic component may be a component that does not volatilize in the air and affects the properties of the liquid such as surface tension. The hydrophobic component can be fat.

As used herein, "fat (component)" includes all solid fats, liquid fats, fatty acids and the like. For example, the solid or liquid fats include, but are not limited to, fatty acid triglycerides, rearranged or randomized fats, transesterified fats that occur naturally in vegetable or animal fats and oils. For example, the fatty acids include saturated or unsaturated (mono-, di- or poly-unsaturated) carboxylic acids containing 10 to 22, such as 12 to 24 carbon atoms. For example, the saturated fatty acid may include capric acid, lauric acid, myristic acid, palmitic acid, stearic acid or behenic acid, and the unsaturated fatty acid may include oleic acid, linoleic acid or erucic acid, but is not limited thereto. no.

As used herein, "trans fat" refers to unsaturated fats containing trans fatty acids. Trans fats increase LDL cholesterol in the body while also lowering HDL cholesterol in the blood. As used herein, "trans fatty acid" means a fatty acid that is typically produced by partial hydrogenation of unsaturated fatty acid vegetable oils. At this time, the term "trans" refers to a position where hydrogen atoms oppose when the unsaturated fat is partially hydrogenated.

As used herein, "solid" means a solid having at least a certain parallel plane on which droplets can be loaded. The solid may be a hydrophobic or water repellent solid, for example, teflon, but is not limited thereto. Hydrophobic components, such as fats, adhere well to hydrophobic surfaces, which can greatly increase the sensitivity of CADF measurements. For example, in one embodiment of the present invention, when using a teflon plate as a solid, up to 1 ppm detection resolution can be obtained.

As used herein, the "contact area of droplets (A ₀ , A _t ) "means the area of the portion where the droplet directly contacts the surface of the solid. The contact area of the droplet may be a sensor provided on the surface of the solid or the contact surface of the droplet and the surface of the solid. Orientation, for example, it can be measured by a method such as calculating the area of the contact surface after the shooting on the lower surface of the solid, but is not limited thereto.

As used herein, the "contact diameter of the droplet (d ₀ , d _t ) "means the length of the portion where the droplet is in direct contact with the surface of the solid observed in an arbitrary direction. The contact diameter of the droplet is obtained by using a sensor provided on the surface of the solid or the droplet and the solid. The contact surface of the surface may be measured by a method such as calculating the length of the contact diameter after photographing in one direction, for example, but not limited thereto.

As used herein, "contact angle (α)" means the angle formed between the surface of the solid and the line in contact with the droplet radius from the point of contact with the solid.

As used herein, “predetermined time (t)” refers to a time sufficient for a contact area diffusion (CAD) phenomenon to occur between a droplet and a solid surface, for example 5 minutes to 1 hour, such as 10 minutes. To 30 minutes, such as 20 minutes. The predetermined time t may be adjusted according to measurement conditions such as fat concentration, temperature and humidity.

2 shows the CADF values of urine before (without fatty component) and after (without fatty component) liposuction. The horizontal axis represents elapsed time (minutes) and the vertical axis represents CADF values.

As shown in FIG. 2, corresponding to the fat content in the urine, the CADF value is negative when the fat component is not contained in the urine, and the CADF value is positive when the fat component is contained in the urine. Using this, it can be confirmed that it is possible to detect the content of the fat component contained in the liquid.

The fat-free urine's CADF value is measured negatively. That is, since the contact angle is maintained, as the water evaporates, the contact area and / or contact diameter of the urine droplet containing no fat decreases. In contrast, CADF values in urine containing fat are measured positive. That is, after a predetermined time elapses, the contact area and / or the contact diameter of the droplets are enlarged than the initial droplets.

3 shows the CADF of urine samples collected every 0.5 days after liposuction. The CADF was measured four times per sample to calculate the mean and standard deviation.

According to FIG. 3, the CADF of the urine sample collected 2.5 days after the liposuction was the largest and became negative after 3.5 days. This is consistent with the fact that patients who have undergone liposuction recover on average after 3 days. It is also shown that the sensitivity of fatty acid content in urine is high enough that the effects of medical treatments, such as compression bandages or infusions, are manifested in CADF values.

Figure 4 shows the relationship between the concentration of fat component and CADF obtained by varying the fat content concentration by diluting the urine sample containing fat component with ultrapure water after liposuction.

Urine samples containing fat from liposuction patients were diluted with ultrapure water to prepare relative concentrations from 100% (pure urine) to 0.4%. As the relative concentration decreased, the CADF also decreased, indicating a monotonic proportional relationship. This confirms that CADF can be used to quantify fat concentration.

Given that the CADF according to one embodiment measures the change in surface energy due to the adsorption of fat to the solid surface, the concentration of CADF and fat component is monotonically proportional. Therefore, the concentration of fat content is formulated using a monotonic function such as an exponential function, a linear function, and a logarithmic function as shown in Equation 2 below.

[Equation 2]

The fat concentration value measured by the GC method is applied to Equation 2, and the correction coefficients may be determined and expressed as a simple monotonic increasing index function as in Equation 3 below.

[Equation 3]

The CADF value measured by the CADF measurement method and Equation 3 according to an embodiment may quantify the fat content of the aqueous fluid as in the GC measurement method. However, the correction constant value used in Equation 2 is not limited to the correction constant used in Equation 3.

In one embodiment, the absolute concentration of fat in a urine sample containing fat taken from a liposuction patient by gas chromatography (GC) analysis is measured, CADF for the same sample is measured, and then the comparison is performed through the correction. The correction coefficients of Equation 2 were determined and the results compared to those shown in FIG. 5. Based on the GC analysis, the equation for C _CADF can be determined as follows, with a correction constant A of 2.03, P of 3.65, Q of 5.53, D of 10, and k, C ₀ and B determined to be 0:

FIG. 6 shows a correlation between low density lipoprotein (LDL) levels and CADF levels among fat components in blood samples. Through this, it was confirmed that the LDL value was proportional to the CADF, while the high density lipoprotein (HDL) value was not correlated with the CADF. This shows that the CADF according to an embodiment can be more sensitively measured in saturated fat and trans fat, etc., which adhere better to blood vessel walls.

Another embodiment of the present invention provides a method for predicting the occurrence of metabolic disease or dementia or providing information on the development or progress of metabolic disease or dementia, using the method for quantifying hydrophobic components contained in a liquid according to the embodiment. to provide.

Specifically, the method of predicting the possibility of developing the metabolic disease or dementia or providing information on the onset or course of the metabolic disease or dementia may include the following steps:

a) contacting droplets of the body fluid to be judged with a solid surface and measuring an initial area A ₀ of the contact surface between the droplet and the solid surface and an initial diameter d ₀ of the contact surface;

b) after a predetermined time _t , measuring the area A _t of the contact surface between the droplet and the solid surface and the diameter d _t of the contact surface;

c) obtaining a contact surface diffusion coefficient (CADF) according to Equation 1 below;

[Equation 1]

(Wherein n, m, N and M are constants)

d) using the contact surface diffusion coefficient and the following formula 2 to obtain the content of the fat component contained in the droplets; And

[Equation 2]

(Wherein k, C ₀ , A, B, D, P and Q are correction constants)

e) comparing the content of fat components obtained with the content of fat components obtained from the body fluids of normal persons.

If the difference in the amount of fat component obtained from the body fluid of the normal person from the content of the fat component obtained from the body fluid of the judgment object is positive, it is determined that there is a high possibility of the occurrence of metabolic disease or dementia, or the development or progress of metabolic disease or dementia Can be diagnosed.

As used herein, "metabolic disease" includes obesity, nonalcoholic liver disease, glucose tolerance, hyperinsulinemia, hyperglycemia, diabetes, hypertension, arteriosclerosis, hyperlipidemia or fatty embolism, preferably diabetes or fatty embolism It may be, but is not limited thereto.

As used herein, "dementia" includes, but is not limited to, Alzheimer's disease, Parkinson's disease vascular dementia, mixed dementia, mild cognitive impairment.

7 shows patients with six diseases, namely diabetes (DM), Alzheimer's disease (AD), Parkinson's disease dementia (PDD), vascular dementia (VD), mild cognitive impairment (MCI) and mixed dementia (AD + VD) Urine free fatty acid preclinical test results measured by the GC method and the CADF method according to one embodiment are shown for 400 people and 100 normal people.

According to Figure 7, it can be seen that the content of fat contained in the urine of each patient is much higher than the normal person, it was confirmed that both the GC and CADF measurement results show very similar results.

In particular, the urine of dementia patients, such as Alzheimer's disease (AD) and Parkinson's disease (PDD), showed almost twice as high values as normal people, indicating that the CADF method of the present invention has high diagnostic confidence on these diseases. there was.

In addition, the diabetic patients have lower fatty acid levels than dementia patients, but still higher than normal people CADF method of the present invention can be used as a diagnostic method for diabetes. In the case of diabetes, when using the method according to an embodiment of the present invention, by using a urine sample to perform a convenient and steady diagnostic management at a low cost and can be a great help in managing individual diabetes, blood difficult patient Their blood sugar management can also be a great help.

The method of quantifying fat component using the CADF method according to an embodiment enables diagnosing dementia by measuring the fatty acid content in readily available body fluids such as urine. Therefore, the effects of the implementation of various dementia treatment methods can be easily compared with each other, thereby finding an optimal treatment method for each individual.

By using the method according to an embodiment, diabetes can be diagnosed or managed by measuring the fat content of readily available body fluids such as urine. Therefore, the effects of various diabetes treatment methods can be easily compared with each other, and through this, an optimal diabetes treatment method for each individual can be found.

Using the method according to an embodiment, it is possible to diagnose and prevent fat embolism by measuring the amount of fat component introduced into blood or urine before, during, or after liposuction. Therefore, appropriate medical measures may be taken for the patient before the onset of fat embolism.

The method of measuring CADF according to an embodiment may be applied to a quantitative analysis technique, for example, to measuring the amount of fat contained in a sample. Compared to GC, the CADF method of the present invention is inexpensive, fast and convenient.

To complement conventional analytical techniques such as GC, the CADF measurement of the present invention can be combined with conventional analytical techniques. For example, CADF measurement results according to the present invention can be applied to fat analysis that cannot be measured directly by UV or fluorescence spectroscopy.

According to an embodiment, the CADF method may be applied to body fat management in health care, diet, and obesity.

Another embodiment of the present invention provides an apparatus for quantifying hydrophobic components contained in a liquid, using the method for quantifying hydrophobic components contained in a liquid according to the above embodiment.

Referring to FIG. 8, the apparatus 100 for measuring the concentration of hydrophobic components contained in a liquid includes a measuring unit 110, a calculating unit 120, and an output unit 130. Each component of the concentration measuring device 100 may be implemented in a computing device or in another device operating in conjunction with such a computing device.

The measurement unit 110 is configured to obtain a value of the contact area or the contact diameter of the contact surface of the liquid droplet and the solid surface. The measurement unit 110 may include a solid having a predetermined or more parallel plane on which the droplet can be raised.

The measuring unit 110 includes an imaging device capable of obtaining images of droplets and solids, for example, a charge-coupled device (CCD) camera, an optical sensor, or the like, for calculating the numerical value of the contact area or contact diameter. , But may include a touch sensor provided on the solid phase, but is not limited thereto. The measuring unit 110 may simultaneously measure the contact area or the contact diameter of one or more droplets on the solid. The measurement unit 110 may measure different contact areas or contact diameter values over time with respect to one droplet.

The measurement unit 110 may include a memory device for controlling the position, focus, and the like of the imaging device, and a memory stored in the memory for the obtained contact area or contact diameter.

The calculation unit 120 obtains a contact surface diffusion coefficient (CADF) according to Equation 1 using the obtained contact area or contact diameter, and uses the obtained contact surface diffusion coefficient (CADF) and Equation 2 below. Can be obtained by calculating the content of hydrophobic components contained in the droplets:

[Equation 1]

Wherein n, m, N and M are constants.

[Equation 2]

Where k, C ₀ , A, B, D, P and Q are correction constants.

The calculation unit 120 compares the concentration of hydrophobic components in the liquid in the determination object based on the concentration data of the hydrophobic components in the liquid obtained from a normal person, such as a liquid obtained from a body fluid, and compares the metabolic properties of the determination object. Information on the likelihood of developing a disease or dementia, whether or not it has occurred, or the course of the disease can be obtained.

The output unit 130 may display the concentration of hydrophobic components, such as fat components, contained in the liquid obtained through the above configurations. Alternatively, the output unit 130 displays a predicted result of the possibility of developing a metabolic disease or dementia in the object of determining the concentration of the obtained hydrophobic component, or provides information on whether or not the metabolic disease or dementia develops or progresses. It can also be displayed.

So far I looked at the center of the preferred embodiment for the present invention. Those skilled in the art will appreciate that the present invention can be implemented in a modified form without departing from the essential features of the present invention. Therefore, the disclosed embodiments should be considered in descriptive sense only and not for purposes of limitation. The scope of the present invention is shown by the following claims rather than the foregoing description, and all changes or modifications derived from the meaning and scope of the claims and their equivalents are included in the scope of the present invention. Should be.

Claims

a) contacting a droplet of liquid to a solid surface and measuring an initial area A 0 of the contact surface between the droplet and the solid surface and an initial diameter d 0 of the contact surface;

b) after a predetermined time t , measuring the area A t of the contact surface between the droplet and the solid surface and the diameter d t of the contact surface; And

c) obtaining a contact surface diffusion coefficient (CADF) according to Equation 1 below.

[Equation 1]

(Wherein n, m, N and M are constants)

Method for quantifying hydrophobic components contained in a liquid comprising a.
According to claim 1,

d) obtaining the content of the hydrophobic component contained in the droplet by using the contact surface diffusion coefficient and the following equation (2): a method for quantifying the hydrophobic component contained in the liquid, characterized in that:

[Equation 2]

(Wherein k, C 0 , A, B, D, P and Q are correction constants)
According to claim 1,

The liquid is a method of quantifying the hydrophobic component contained in the liquid, characterized in that the body fluid.
The method of claim 3, wherein

The body fluid is a method for quantifying hydrophobic components contained in a liquid, characterized in that selected from the group consisting of blood, serum, plasma, sweat and urine
According to claim 1,

The hydrophobic component is a method for quantifying the hydrophobic component contained in the liquid, characterized in that the fat.
a) contacting droplets of the body fluid to be judged with a solid surface and measuring an initial area A 0 of the contact surface between the droplet and the solid surface and an initial diameter d 0 of the contact surface;

b) after a predetermined time t , measuring the area A t of the contact surface between the droplet and the solid surface and the diameter d t of the contact surface;

c) obtaining a contact surface diffusion coefficient (CADF) according to Equation 1 below;

[Equation 1]

(Wherein n, m, N and M are constants)

d) using the contact surface diffusion coefficient and the following formula 2 to obtain the content of the fat component contained in the droplets; And

[Equation 2]

(Wherein k, C 0 , A, B, D, P and Q are correction constants)

e) comparing the content of the fat component obtained with the content of the fat component obtained from the body fluids of normal persons

Method of providing information on the prediction of the occurrence of metabolic disease or dementia, including the development or progress of metabolic disease or dementia.
The method of claim 6,

When the difference in the amount of the fat component obtained from the body fluid of the normal person from the content of the fat component obtained from the body fluid of the judgment object is positive, it is highly likely to develop a metabolic disease or dementia or to diagnose the development of metabolic disease or dementia A method of predicting the possibility of developing a metabolic disease or dementia or providing information on the development or progress of a metabolic disease or dementia.
The method of claim 6,

The body fluid is selected from the group consisting of blood, serum, plasma, sweat and urine, the method of predicting the possibility of the development of metabolic disease or dementia or providing information on the development or progress of metabolic disease or dementia.
The method of claim 6,

The metabolic disease is selected from the group consisting of diabetes mellitus and fat embolism predicting the occurrence of metabolic disease or dementia or providing information on the development or progress of metabolic disease or dementia.
The method of claim 6,

The dementia is selected from the group consisting of Alzheimer's disease, Parkinson's disease, vascular dementia, mixed dementia and mild cognitive impairment, providing information on the prediction of the development of metabolic disease or dementia or the development or progress of metabolic disease or dementia. Way.